Kexing Biopharm Co Ltd
SSE:688136
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Kexing Biopharm Co Ltd
Research & Development
Kexing Biopharm Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kexing Biopharm Co Ltd
SSE:688136
|
Research & Development
-¥140.7m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Research & Development
-¥13.6B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Research & Development
-¥2.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Research & Development
-¥1.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Research & Development
-¥1.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Research & Development
-¥1.3B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Kexing Biopharm Co Ltd
Glance View
Kexing Biopharm Co Ltd, formerly Shan Dong Kexing Bioproducts Co Ltd, is a China-based company principally involved in the research and development, manufacturing and sales of recombinant protein drugs and microecological preparations. Its products are the recombinant protein therapeutics 'Recombinant Human Erythropoietin', 'Recombinant Human Interferon α1b and Recombinant Human Granulocyte Colony-stimulating Factor, as well as the microbiota agents Combined Clostridium Butyricum and Bifidobacterium, etc. The Company's products are used for the therapeutic fields of antiviral, hematology, oncology and immunology, and degenerative diseases
See Also
What is Kexing Biopharm Co Ltd's Research & Development?
Research & Development
-140.7m
CNY
Based on the financial report for Dec 31, 2024, Kexing Biopharm Co Ltd's Research & Development amounts to -140.7m CNY.
What is Kexing Biopharm Co Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-29%
Over the last year, the Research & Development growth was 55%. The average annual Research & Development growth rates for Kexing Biopharm Co Ltd have been -8% over the past three years , -29% over the past five years .
